Brian Van Tine, MD, PhD

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Acuta Capital Partners, LLC
    Topic: 
    Consulting
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Aadi
    Topic: 
    Consulting/ Attended an advisory board meeting
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Race Oncology
    Topic: 
    Consulting
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Hinge Bio
    Topic: 
    Consulting
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Kronos Bio
    Topic: 
    Consulting
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Travel
    Ineligible company: 
    Kronos Bio
    Topic: 
    Travel to meeting
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Iterion Therapeutics, Inc.
    Topic: 
    Consulting
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Total Health Conference
    Topic: 
    Educational Talk
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Travel
    Ineligible company: 
    Total Health Conference
    Topic: 
    Travel to speak at conference.
    Date added: 
    08/11/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Travel
    Ineligible company: 
    Adaptimmune
    Topic: 
    Travel to speak at Conference
    Date added: 
    08/11/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond